Program Description

Research in the development of targeted biologic therapies for cancer treatment continues to evolve at a rapid pace. This research has produced promising results with the development of agents that target characteristics of specific malignant cells. Targeted therapies differ significantly in terms of their mechanisms of action, biologic targets, and method of production. For example, advances in methods of monoclonal antibody (MAb) generation have led to the development of MAb therapies that are less antigenic, have improved safety profiles, and potentially more effective than early MAb therapies.

Certain cancers, particularly breast, colon, lung, and hematologic malignancies, have been closely associated with targeted therapy research for a number of years. In particular, research over the last few years has shown agents which target the Epidermal Growth Factor Receptor (EGFR) to be effective in the treatment of colorectal cancer.

Speakers will discuss the various types of monoclonal antibodies and their respective pathways of generation and safety and efficacy profiles. The rationale and importance of developing purely human monoclonal antibody therapies will be explained. Also, the role of EGFR in cancer development and as a therapeutic target in cancer treatment will be addressed. Finally, treatment of colorectal cancer, the second leading cause of cancer death in the U.S., will be discussed with an emphasis on incorporation of targeted therapies into current and future regimens.

As new targeted therapies continue to emerge, pharmacists involved in the care of oncology patients will require new skills and knowledge to assure these agents are used safely and effectively.

Target Audience

This symposium was planned to meet the needs of pharmacists in a variety of healthcare settings, including large and small hospitals, managed care facilities, inpatient facilities, as well as the pharmaceutical industry and academia. The program would be beneficial for those who have an interest or practice in oncology.